CareDx (CDNA) Stock Price

CareDx Price

NASDAQ·CLOSED
46.35USD-1.36 (-2.89 %)
Market closed

Revenue has compounded at 42.9% per year over the past 20 years to 379.81 M USD. CareDx's net margin stands at -5.6%, up from -10.3% several years earlier. Analysts set a median price target of 25.50 USD, implying 45.0% below the current price. Of 14 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 301% above its 52-week low.

CareDx stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of CareDx over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how CareDx stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing CareDx's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

CareDx Stock Price History
DateCareDx Price
8/5/202646.35 USD
8/4/202647.71 USD
8/3/202647.85 USD
7/31/202643.71 USD
7/30/202638.10 USD
7/29/202635.45 USD
7/27/202637.01 USD
7/23/202637.61 USD
7/22/202637.78 USD
7/21/202638.54 USD
7/20/202638.37 USD
7/17/202639.73 USD
7/16/202640.34 USD
7/15/202629.75 USD
7/14/202628.93 USD
7/13/202628.54 USD
7/10/202628.51 USD
7/9/202629.11 USD
7/8/202628.22 USD
7/7/202628.31 USD
7/6/202629.09 USD
7/2/202629.19 USD
7/1/202629.25 USD
6/30/202628.50 USD
6/29/202629.23 USD
6/26/202628.82 USD
6/25/202627.85 USD
6/24/202627.13 USD
6/23/202625.12 USD
6/22/202625.26 USD
6/18/202624.52 USD
6/17/202623.97 USD
6/16/202624.72 USD
6/15/202623.72 USD
6/12/202623.48 USD
6/11/202623.27 USD
6/10/202622.70 USD
6/9/202622.75 USD
6/8/202621.95 USD
6/5/202622.32 USD
6/4/202623.19 USD
6/3/202622.06 USD
6/2/202621.90 USD
6/1/202622.63 USD
5/29/202622.95 USD
5/28/202622.60 USD
5/27/202621.64 USD
5/26/202621.82 USD
5/22/202621.50 USD
5/21/202621.82 USD
5/20/202620.99 USD
5/19/202620.53 USD
5/18/202620.59 USD
5/15/202619.97 USD
5/14/202620.49 USD
5/13/202620.61 USD
5/12/202621.40 USD
5/11/202621.55 USD
5/8/202621.82 USD
5/7/202621.44 USD
5/6/202620.95 USD
5/5/202620.70 USD
5/4/202620.96 USD
5/1/202621.50 USD
4/30/202620.81 USD
4/29/202620.80 USD
4/28/202621.91 USD
4/27/202621.85 USD
4/24/202621.23 USD
4/22/202620.63 USD
4/21/202620.73 USD
4/20/202621.29 USD
4/17/202621.42 USD
4/16/202622.42 USD
4/15/202617.57 USD
4/14/202617.63 USD
4/13/202616.83 USD
4/10/202616.05 USD
4/9/202616.69 USD
4/8/202617.92 USD
4/7/202617.67 USD
4/6/202617.82 USD
4/2/202618.31 USD
4/1/202617.87 USD
3/31/202617.36 USD
3/30/202616.43 USD
3/27/202616.78 USD
3/26/202617.47 USD
3/25/202618.08 USD
3/24/202617.84 USD
3/23/202617.56 USD
3/20/202617.15 USD
3/19/202617.59 USD
3/18/202617.38 USD
3/17/202617.60 USD
3/16/202617.32 USD
3/13/202617.01 USD
3/12/202616.45 USD
3/11/202617.15 USD
3/10/202616.98 USD
3/9/202617.74 USD
3/6/202617.89 USD
3/5/202618.75 USD
3/4/202619.06 USD
3/3/202618.80 USD
3/2/202618.75 USD
2/27/202618.76 USD
2/26/202618.82 USD
2/25/202618.46 USD
2/24/202619.25 USD
2/23/202618.79 USD
2/20/202618.80 USD
2/19/202619.87 USD
2/18/202619.93 USD
2/17/202619.44 USD
2/13/202619.63 USD
2/12/202619.10 USD
2/11/202619.72 USD
2/10/202620.57 USD
2/9/202620.19 USD
2/6/202619.47 USD
2/5/202618.35 USD
2/4/202618.93 USD
2/3/202620.63 USD
2/2/202620.42 USD
1/30/202620.55 USD
1/29/202620.80 USD
1/28/202620.46 USD
1/27/202620.58 USD
1/26/202620.80 USD
1/23/202620.42 USD
1/22/202621.02 USD
1/21/202620.83 USD
1/20/202620.20 USD
1/16/202620.01 USD
1/15/202620.57 USD
1/14/202620.32 USD
1/13/202620.19 USD
1/12/202620.57 USD
1/9/202617.13 USD
1/8/202617.22 USD
1/7/202618.90 USD
1/6/202618.81 USD
1/5/202619.81 USD
1/2/202619.14 USD
12/31/202518.84 USD
12/30/202519.07 USD
12/29/202519.20 USD
12/26/202519.48 USD
12/24/202519.73 USD
12/23/202520.02 USD
12/22/202520.02 USD
12/19/202519.45 USD
12/18/202519.19 USD
12/17/202519.49 USD
12/16/202519.36 USD
12/15/202519.91 USD
12/12/202520.56 USD
12/11/202519.80 USD
12/10/202519.55 USD
12/9/202519.25 USD
12/8/202518.90 USD
12/5/202518.53 USD
12/4/202519.41 USD
12/3/202518.85 USD
12/2/202517.44 USD
12/1/202517.18 USD
11/28/202517.87 USD
11/26/202517.81 USD
11/25/202517.90 USD
11/24/202517.96 USD
11/21/202517.18 USD
11/20/202515.76 USD
11/19/202515.98 USD
11/18/202515.76 USD
11/17/202515.51 USD
11/14/202515.94 USD
11/13/202515.87 USD
11/12/202516.31 USD
11/11/202516.78 USD
11/10/202516.70 USD
11/7/202515.62 USD
11/6/202515.01 USD
11/5/202516.53 USD
11/4/202514.52 USD
11/3/202514.77 USD
10/31/202515.00 USD
10/30/202514.47 USD
10/29/202514.28 USD
10/28/202514.67 USD
10/27/202514.51 USD
10/24/202514.97 USD
10/23/202514.70 USD
10/22/202514.58 USD
10/21/202515.19 USD
10/20/202515.22 USD
10/17/202514.41 USD
10/16/202514.99 USD
10/15/202514.70 USD
10/14/202514.35 USD
10/13/202514.53 USD
10/10/202514.39 USD
10/9/202514.73 USD
10/8/202514.79 USD
10/7/202514.67 USD
10/6/202514.96 USD
10/3/202515.19 USD
10/2/202514.84 USD
10/1/202515.00 USD
9/30/202514.54 USD
9/29/202514.86 USD
9/26/202514.93 USD
9/25/202514.87 USD
9/24/202515.06 USD
9/23/202515.57 USD
9/22/202514.99 USD
9/19/202514.59 USD
9/18/202514.77 USD
9/17/202514.30 USD
9/16/202514.18 USD
9/15/202514.02 USD
9/12/202513.53 USD
9/11/202513.53 USD
9/10/202513.33 USD
9/9/202513.45 USD
9/8/202513.34 USD
9/5/202513.82 USD
9/4/202513.10 USD
9/3/202512.73 USD
9/2/202513.85 USD
8/29/202513.66 USD
8/28/202513.11 USD
8/27/202513.29 USD
8/26/202512.81 USD
8/25/202512.75 USD
8/22/202512.97 USD
8/21/202512.51 USD
8/20/202512.17 USD
8/19/202511.57 USD
8/18/202511.85 USD
8/15/202511.84 USD
8/14/202511.82 USD
8/13/202512.13 USD
8/12/202512.46 USD
8/11/202511.77 USD
8/8/202511.97 USD
8/7/202512.07 USD
Access this data via the Eulerpool API
Get Free API Key

CareDx Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
296.40 M USD
-29.73 M USD
-30.66 M USD
Jan 1, 2022
321.79 M USD
-77.23 M USD
-76.61 M USD
Jan 1, 2023
280.32 M USD
-203.36 M USD
-190.28 M USD
Jan 1, 2024
333.79 M USD
40.77 M USD
52.55 M USD
Jan 1, 2025
379.81 M USD
-21.02 M USD
-21.35 M USD
Jan 1, 2026 (e)
455.93 M USD
-85.29 M USD
48.04 M USD
Jan 1, 2027 (e)
481.27 M USD
-90.03 M USD
58.33 M USD
Jan 1, 2028 (e)
507.21 M USD
-94.89 M USD
78.65 M USD

CareDx Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 7, 2026, 10:51 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20132014201520162017201820192020202120222023202420252026e2027e2028e
22.0027.0028.0040.0048.0076.00127.00192.00296.00321.00280.00333.00379.00455.00481.00507.00
10.0022.733.7042.8620.0058.3367.1151.1854.178.45-12.7718.9313.8120.055.715.41
59.0966.6760.7147.5054.1756.5863.7867.1967.2365.1163.5767.2767.0267.0267.0267.02
13.0018.0017.0019.0026.0043.0081.00129.00199.00209.00178.00224.00254.00304.93322.36339.78
–1.00-11.00-20.00-18.00-15.00-24.00-22.00-29.00-77.00-203.0040.00-21.00-85.00-90.00-94.00
–3.70-39.29-50.00-37.50-19.74-18.90-11.46-9.80-23.99-72.5012.01-5.54-18.68-18.71-18.54
-3.00–-13.00-39.00-55.00-46.00-21.00-18.00-30.00-76.00-190.0052.00-21.0048.0058.0078.00
-40.00––200.0041.03-16.36-54.35-14.2966.67153.33150.00-127.37-140.38-328.5720.8334.48
7.3712.1311.9021.2727.9840.1042.4649.3352.8553.5252.7358.2251.1251.1251.1251.12
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales CareDx generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue CareDx retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare CareDx's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares CareDx has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against CareDx's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

CareDx stock margins

The CareDx margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CareDx. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CareDx.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
67.14 %
-10.03 %
-10.34 %
Jan 1, 2022
65.13 %
-24.00 %
-23.81 %
Jan 1, 2023
63.61 %
-72.55 %
-67.88 %
Jan 1, 2024
67.16 %
12.21 %
15.74 %
Jan 1, 2025
66.99 %
-5.53 %
-5.62 %
Jan 1, 2026 (e)
66.99 %
-18.71 %
10.54 %
Jan 1, 2027 (e)
66.99 %
-18.71 %
12.12 %
Jan 1, 2028 (e)
66.99 %
-18.71 %
15.51 %

CareDx Stock Revenue, EBIT, Earnings per Share

The CareDx earnings per share therefore indicates how much revenue CareDx has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
5.61 USD
-0.56 USD
-0.58 USD
Jan 1, 2022
6.01 USD
-1.44 USD
-1.43 USD
Jan 1, 2023
5.32 USD
-3.86 USD
-3.61 USD
Jan 1, 2024
5.73 USD
0.70 USD
0.90 USD
Jan 1, 2025
7.43 USD
-0.41 USD
-0.42 USD
Jan 1, 2026 (e)
8.87 USD
-1.67 USD
0.93 USD
Jan 1, 2027 (e)
9.36 USD
-1.76 USD
1.13 USD
Jan 1, 2028 (e)
9.86 USD
-1.86 USD
1.53 USD

CareDx business model & stock analysis

CareDx Inc is a US-based company specializing in diagnostic solutions for the transplantation industry. The company was founded in 1998 and is at the forefront of developing tests for transplant patients.

CareDx SWOT Analysis

Strengths

CareDx Inc is a leader in the field of transplant diagnostics, providing innovative solutions for organ transplant patients and healthcare professionals. The company has established a strong reputation for its high-quality products and services.

CareDx Inc has a diverse and experienced team of professionals who possess deep knowledge and expertise in transplant medicine, molecular diagnostics, and bioinformatics. This allows the company to develop advanced diagnostic tools and technologies that meet the specific needs of transplant patients.

The company's product portfolio includes a range of diagnostic tests that help assess the risk of rejection in organ transplant recipients, monitor post-transplant health, and guide personalized treatment decisions. These tests have the potential to improve patient outcomes and reduce healthcare costs.

CareDx Inc has established strong relationships with transplant centers, hospitals, and clinics worldwide, providing them with reliable diagnostic solutions and support. This widespread adoption of the company's products contributes to its continued growth and market leadership.

Weaknesses

As a specialized company focused on transplant diagnostics, CareDx Inc may be vulnerable to changes in regulations or reimbursement policies that affect the transplant industry. These regulatory uncertainties can impact the demand and usage of the company's products.

The company's reliance on a limited number of key customers, such as transplant centers, may pose a risk to its business. Any significant loss of these key customers could have a negative impact on CareDx Inc's revenue and market share.

CareDx Inc's heavy investment in research and development (R&D) to develop innovative products and technologies may result in increased expenses and financial risks. The success and commercialization of these R&D efforts are not guaranteed, and any setbacks could adversely affect the company's financial performance.

Opportunities

The increasing demand for transplant procedures, driven by the growing prevalence of organ failure and advancements in transplantation techniques, presents opportunities for CareDx Inc to expand its customer base and revenue. The company can capitalize on this trend by enhancing its diagnostic capabilities and continuously developing new solutions.

Expanding into emerging markets, where transplant diagnostics may be underdeveloped, can be a strategic opportunity for CareDx Inc. By establishing partnerships or alliances with local healthcare providers, the company can introduce its products and services to a wider audience and gain a competitive edge.

The advancements in genomics and personalized medicine offer the potential for CareDx Inc to further tailor its diagnostic tools and provide personalized transplant solutions. By leveraging these technologies, the company can enhance patient care and differentiate itself from competitors.

Threats

Competition from other companies operating in the transplant diagnostics market poses a threat to CareDx Inc's market share. These competitors may offer similar products or develop alternative diagnostic technologies that could disrupt the market and capture a portion of CareDx Inc's customer base.

Changes in healthcare policies and insurance coverage can impact the demand for CareDx Inc's products. Reduced reimbursement rates or limitations in coverage for transplant diagnostics could affect the company's ability to generate revenue and maintain profitability.

The unpredictable nature of organ availability and the success of transplant procedures can also pose a threat to CareDx Inc. If the number of transplant procedures declines or if organ rejection rates decrease significantly, the demand for the company's diagnostic tests may be affected.

CareDx Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

CareDx Employees
Details
Date
CareDx Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

CareDx Segments

CareDx Revenue by Segment (1/6)

  • Max

Testing services revenue
Patient and digital solutions revenue
Product revenue
Patient and digital solutions
Details
Date
Testing services revenue
Service
Patient and digital solutions revenue
Product revenue
Patient and digital solutions
Digital and other revenue
Jan 1, 2016
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
249.38 M USD
0.00 USD
0.00 USD
40.78 M USD
43.62 M USD
0.00 USD
Jan 1, 2025
274.50 M USD
0.00 USD
56.93 M USD
48.38 M USD
0.00 USD
0.00 USD

CareDx Revenue by Segment (2/6)

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
Testing services revenue
Product revenue
Digital and other
Product
Testing Services
License and other
Jan 1, 2016
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

CareDx Revenue by Segment (3/6)

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
Digital and other revenue
Testing
Jan 1, 2016
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD

CareDx Revenue by Segment (4/6)

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
Royalty
Jan 1, 2016
0.00 USD
Jan 1, 2017
0.00 USD
Jan 1, 2024
0.00 USD
Jan 1, 2025
0.00 USD

CareDx Revenue by Segment (5/6)

  • 3 Years

  • 5 Years

  • Max

Pre transplant
Details
Date
Pre transplant
Jan 1, 2016
0.00 USD
Jan 1, 2017
14.63 M USD
Jan 1, 2024
0.00 USD
Jan 1, 2025
0.00 USD

CareDx Revenue by Segment (6/6)

  • 3 Years

  • 5 Years

  • Max

Reportable Segment
Post transplant
CareDx
Olerup
Details
Date
Reportable Segment
Post transplant
CareDx
Olerup
Jan 1, 2016
0.00 USD
0.00 USD
29.92 M USD
10.71 M USD
Jan 1, 2017
0.00 USD
33.69 M USD
0.00 USD
0.00 USD
Jan 1, 2024
333.79 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
379.81 M USD
0.00 USD
0.00 USD
0.00 USD

CareDx Revenue by Region

  • 3 Years

  • 5 Years

  • Max

United States
North America
International
Europe
Europe, Middle East and Africa
Latin America
Australia
Details
Date
United States
North America
International
Europe
Europe, Middle East and Africa
Latin America
Australia
Jan 1, 2018
66.06 M USD
0.00 USD
2.90 M USD
7.60 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
116.20 M USD
0.00 USD
3.08 M USD
7.79 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
181.50 M USD
0.00 USD
3.13 M USD
7.56 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
282.01 M USD
0.00 USD
4.57 M USD
9.82 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
307.54 M USD
0.00 USD
4.70 M USD
9.55 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
265.63 M USD
0.00 USD
4.53 M USD
10.17 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
317.73 M USD
0.00 USD
5.38 M USD
10.67 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
359.94 M USD
0.00 USD
19.87 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

CareDx Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

CareDx historical P/E ratio, EBIT multiple, and P/S ratio

CareDx annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

CareDx shares outstanding

The number of shares of CareDx was 51.12 M in 2025. This indicates how many shares CareDx is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
52.85 M Stocks
Jan 1, 2022
53.52 M Stocks
Jan 1, 2023
52.73 M Stocks
Jan 1, 2024
58.22 M Stocks
Jan 1, 2025
51.12 M Stocks
Jan 1, 2026 (e)
51.12 M Stocks
Jan 1, 2027 (e)
51.12 M Stocks
Jan 1, 2028 (e)
51.12 M Stocks

Current CareDx forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
1.96 %
Buy
57.14 % (8)
Hold
42.86 % (6)
Sell
0.00 % (0)
12M Price Target
25.50
Last Price
46.35
Currency
USD
12M Return Potential
-44.98 %
LTM Return
0 %

CareDx Analyst Rating Actions

DateFirmActionRatingReliability
7/31/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedNeutral–
7/16/2026
BTIG
BTIG
MaintainedBuy–
4/29/2026
BTIG
BTIG
MaintainedBuy–
2/26/2026
BTIG
BTIG
MaintainedBuy–
2/25/2026
Wells Fargo
Wells Fargo
MaintainedEqual Weight56
12/15/2025
Wells Fargo
Wells Fargo
MaintainedEqual Weight56
11/6/2025
BTIG
BTIG
MaintainedBuy–
9/23/2025
BTIG
BTIG
MaintainedBuy–
9/12/2025
BTIG
BTIG
MaintainedBuy–
8/8/2025
Wells Fargo
Wells Fargo
MaintainedEqual Weight56

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

CareDx Earnings Calls

2025

CareDx Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
7/30/20260.24USD-116.33 MUSD-2026 Q2
4/30/20260.14USD-104.33 MUSD-2026 Q1
3/4/20260.24USD-105.31 MUSD-2025 Q4
11/6/20240.00USD-81.14 MUSD-2024 Q3
5/8/2024-0.20USD-62.91 MUSD-2024 Q1
2/26/2024-0.29USD-62.93 MUSD-2023 Q4
8/2/2023-0.03USD-88.22 MUSD-2023 Q2
5/3/2023-0.05USD-85.48 MUSD-2023 Q1
2/22/2023-0.10USD-82.85 MUSD-2022 Q4
11/3/2022-0.14USD-83.86 MUSD-2022 Q3

EESG©

Eulerpool ESG Scorecard© for the CareDx stock

82/100
83
Environment
97
Social
64
Governance
E

Environment

20
Scope 1 - Direct Emissions1,080.02
Scope 2 - Indirect emissions from purchased energy525
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions525
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees58
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

CareDx shareholder structure

% Name
8.79272%
BLACKROCK, INC.
BLACKROCK, INC.
6.48728%
BAMCO INC /NY/
BAMCO INC /NY/
5.36727%
STATE STREET CORP
STATE STREET CORP
4.33124%
ARK INVESTMENT MANAGEMENT LLC
ARK INVESTMENT MANAGEMENT LLC
4.26016%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
4.22544%
BRAIDWELL LP
BRAIDWELL LP
...

CareDx Beneficial Ownership Filings (SEC 13D/G)

Free Float
95.5%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
11.00%
Ivy Investment Management Company Tax ID No. 03-0481447
Ivy Investment Management Company Tax ID No. 03-0481447
SEC ↗
10.87%
Fred Alger Management, LLC
Fred Alger Management, LLC
SEC ↗
10.87%
Alger Group Holdings, LLC
Alger Group Holdings, LLC
SEC ↗
10.31%
Fred Alger & Company, Incorporated – 13-2665689
Fred Alger & Company, Incorporated – 13-2665689
SEC ↗
9.98%
The Vanguard Group - 23-1945930
The Vanguard Group - 23-1945930
SEC ↗
9.90%
Page 5 of 10
Page 5 of 10
SEC ↗
9.10%
James G. Coulter
James G. Coulter
SEC ↗
9.10%
David Bonderman
David Bonderman
SEC ↗
8.00%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
7.48%
ArrowMark Colorado Holdings, LLC
ArrowMark Colorado Holdings, LLC
SEC ↗

CareDx Executives and Management Board

16 members · avg. age 61 · 31 % women

JH

Mr. John Hanna (45)

President, Chief Executive Officer, Director · since 2024

9.42 M USD

Management

KK

Mr. Keith Kennedy (55)

Chief Operating Officer

4.51 M USD
JM

Ms. Jessica Meng (50)

Chief Commercial Officer

3.39 M USD
JN

Mr. Jeffrey Novack (42)

General Counsel, Secretary

1.28 M USD
NS

Mr. Nathan Smith (48)

Chief Financial Officer

–
JF

Ms. Jennifer Foley

Chief Product Officer

–
CC

Ms. Caroline Corner

Investor Relations · since 2025

–

Board of Directors

MG

Mr. Michael Goldberg (67)

Independent Chairman of the Board · since 2011

743,374.00 USD
RR

Mr. R. Bryan Riggsbee (54)

Independent Director

552,568.00 USD
CC

Ms. Christine Cournoyer (73)

Independent Director

372,303.00 USD
GB

Mr. George Bickerstaff (69)

Independent Director

366,060.00 USD
HV

Dr. Hannah Valantine (73)

Independent Director

357,771.00 USD
WH

Mr. William Hagstrom (67)

Independent Director

357,070.00 USD

Frequently asked questions about CareDx

The business model of CareDx Inc. revolves around providing personalized medicine solutions for transplant patients. CareDx utilizes advanced diagnostic tools and technology to improve the outcome of organ transplant procedures. The company specializes in developing and delivering innovative molecular diagnostic solutions, including its flagship product, AlloSure, which helps assess the health and function of transplanted organs. CareDx Inc. also offers a comprehensive portfolio of transplant surveillance products and services to aid physicians in managing patients post-transplant. With a focus on organ transplant patients, CareDx aims to enhance patient care and optimize transplant outcomes through its cutting-edge molecular diagnostic solutions.

CareDx Inc is primarily active in the biotechnology and healthcare industries.

The main competitors of CareDx Inc in the market include companies such as Natera Inc, Illumina Inc, and Thermo Fisher Scientific Inc.

CareDx Inc is a leading precision medicine company focused on transforming patient care through diagnostic solutions. Established in 1998, CareDx specializes in transplant diagnostics, offering a comprehensive suite of products and services to assess the health of transplanted organs. The company's innovative technologies, such as AlloSure and AlloMap, enable healthcare providers to monitor transplant patients and personalize treatment plans. With a strong commitment to improving outcomes for transplant recipients, CareDx has played a significant role in advancing transplant medicine. CareDx Inc continues to be a trusted name in the healthcare industry, providing valuable insights and solutions for clinicians and patients alike.

CareDx Inc has achieved several significant milestones since its inception. The company has made notable advancements in the field of transplant diagnostics. It has successfully developed and commercialized innovative testing solutions, such as AlloSure and AlloMap, which help healthcare professionals monitor organ transplant recipient's immune system. CareDx Inc has also expanded its portfolio with the acquisition of other diagnostic technologies, allowing it to offer a comprehensive range of solutions. Additionally, the company has collaborated with renowned transplant centers and research institutions, further enhancing its expertise and reputation in the field. These accomplishments demonstrate CareDx Inc's commitment to improving transplant patient outcomes through cutting-edge diagnostics.

CareDx Inc is primarily present in the United States, with its headquarters located in Brisbane, California. As a leading precision medicine company, CareDx focuses on improving patient outcomes through advancing diagnostic solutions for transplant patients. With a wide range of innovative products and services, CareDx aims to optimize transplant management and enhance long-term patient care. While CareDx operates globally, its primary presence remains concentrated within the United States.

CareDx Inc represents values of innovation, patient-centricity, and excellence in personalized medicine. The company is committed to transforming patient care through transplant diagnostics and novel digital health solutions. CareDx emphasizes collaboration with clinicians and industry partners to deliver breakthrough technologies that improve outcomes for transplant patients. With a focus on providing accurate, timely, and actionable information, CareDx strives to empower healthcare professionals with the tools needed to make informed decisions and improve patient lives. By leveraging their expertise in genomics and diagnostic testing, CareDx is driving advancements in the field of transplantation and leading the way in improving the standard of care.

Analysts currently set an average price target of 23.66 USD for the CareDx stock (median: 25.50 USD), implying -48.9 % versus the latest price. The consensus is based on 14 analyst ratings.

CareDx Analyst Price Targets 2026

14 analysts currently rate the CareDx stock: 8 recommend buying, 6 holding and 0 selling. For 2026, analysts expect CareDx to generate revenue of 455.93 M USD and earnings per share of 0.94 USD.

CareDx Analyst Price Targets 2026

Converted at the current exchange rate, the CareDx share trades at 40.20 EUR (46.35 USD).

The CareDx share (CDNA) is listed on 5 stock exchanges, including: NASDAQ (CDNA), Frankfurt (1K9), München (1K9.MU), Düsseldorf (1K9.DU).

CareDx Inc. is a leading company in the field of diagnostic medicine and offers a wide range of products and services for transplant patients. The company is headquartered in Brisbane, California and specializes in the development, manufacturing, and marketing of solutions for monitoring and treating transplant patients. CareDx Inc. is divided into various divisions, each offering different products and services. Here are some of the main divisions of the company: Transplant Diagnostics: This division of CareDx Inc. offers a variety of tests for monitoring transplant patients. These include diagnostic tests for identifying donor and recipient characteristics, blood tests for monitoring immunosuppression, and molecular tests for determining rejection rates. These tests help doctors monitor the status of the transplant and treat it specifically. Transplant Patient Monitoring: This division of CareDx Inc. offers monitoring systems for transplant patients. These systems allow doctors to continuously monitor the patient's condition and detect early signs of rejection or other complications. The systems include devices for measuring weight, blood pressure, pulse, and other vital parameters. Transplant Care: This division of CareDx Inc. offers a wide range of services for transplant patients. These include personal care, patient and caregiver education, and support for accessing treatment services. The goal of these services is to provide comprehensive support to patients and help them achieve optimal outcomes after transplantation. Transplant Business: This division of CareDx Inc. offers specialized products and services for transplant centers and hospitals. These include training for medical staff, consulting services for best practices in transplant medicine, and specialized software for monitoring transplant patients. CareDx Inc. offers a wide range of products and services for transplant patients, all aimed at improving patient outcomes and quality of life. The company has a strong research and development department that continuously strives to develop innovative products and technologies to improve transplant medicine. The company works closely with transplant centers and medical professionals to ensure that patients' needs are met and that they receive optimal care. SEO Optimization: CareDx Inc. is a leading company in the field of diagnostic medicine and offers a wide range of products and services for transplant patients. The company is divided into various divisions, each offering different products and services. CareDx Inc. has a strong research and development department that continuously strives to develop innovative products and technologies. The company works closely with transplant centers and medical professionals to ensure that patients' needs are met. If you are looking for high-quality products and services for transplant patients, then CareDx Inc. is your best choice.

The expected revenue of CareDx is 455.93 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of CareDx is 48.04 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of CareDx is currently 49.33. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the CareDx stock.

The price-to-sales ratio (P/S) of CareDx is currently 5.20. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the CareDx stock.

The Eulerpool Quality Score for CareDx is 3/10.

The ISIN of CareDx is US14167L1035. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of CareDx is A118WG. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of CareDx is CDNA. The ticker symbol is used to trade CareDx shares on the stock exchange.

CareDx paid dividends every year for the past 0 years.

CareDx is assigned to the 'Health' sector.

The dividends of CareDx are distributed in USD.

All fundamentals and in-depth analysis of CareDx

Our stock analysis for CareDx stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CareDx. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

CareDx Stock
CareDx Revenue→
CareDx Stock
CareDx Net Income→
CareDx Stock
CareDx P/E→
CareDx Stock
CareDx P/S→
CareDx Stock
CareDx EBIT→
CareDx Stock
CareDx Dividend→
CareDx Stock
CareDx Directors Dealings→
CareDx Stock
CareDx Stocks→
CareDx Stock
CareDx Market capitalization→
CareDx Stock
CareDx Debt→
CareDx Stock
CareDx Liabilities→
CareDx Stock
CareDx Equity→
CareDx Stock
CareDx AAQS→
CareDx Stock
CareDx Employees→
CareDx Stock
CareDx ROE→
CareDx Stock
CareDx ROA→
CareDx Stock
CareDx ROCE→
CareDx Stock
CareDx News→
CareDx Stock
CareDx Analyst Price Targets→

Health Stocks

Caregen CoCareCloudCareium AB (publ)Care TwentyoneCarelabs CoCare Service CoCarepay HoldingsCardiol TherapeuticsCarePayment TechnologiesCardioGenics HoldingsCareRay Digital Medical Technology CoCardioComm SolutionsAll Stocks A–Z →